Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks Consensus Estimate The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. This biotechnology company is expected to post quarterly loss of $1.64 per share in its upcoming report, which represents a year-over-year change of +27.1%. Estimate Revisions Trend Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggrega ...